Selected research
Industry Research
Resistant Pseudomonas Aeruginosa Infections Drugs Industry Research Report 2026
Market perspective
The global Resistant Pseudomonas Aeruginosa Infections Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Resistant Pseudomonas Aeruginosa Infections Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Resistant Pseudomonas Aeruginosa Infections Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include Achaogen Inc, AmpliPhi Biosciences Corp, Biolytics Pharma, ContraFect Corp, Inhibrx LP, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Shionogi & Co Ltd and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Resistant Pseudomonas Aeruginosa Infections Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Resistant Pseudomonas Aeruginosa Infections Drugs Market by Company
Achaogen Inc
AmpliPhi Biosciences Corp
Biolytics Pharma
ContraFect Corp
Inhibrx LP
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Shionogi & Co Ltd
Novartis AG
Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Type
Cephalosporin
Lactam Drugs
Semi-Synthetic Penicillin
Others
Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Application
Hospital
Clinic
Home Care
Resistant Pseudomonas Aeruginosa Infections Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Resistant Pseudomonas Aeruginosa Infections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Resistant Pseudomonas Aeruginosa Infections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Resistant Pseudomonas Aeruginosa Infections Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Resistant Pseudomonas Aeruginosa Infections Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Resistant Pseudomonas Aeruginosa Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cephalosporin
- Lactam Drugs
- Semi-Synthetic Penicillin
- Others
Applications
- Hospital
- Clinic
- Home Care
Companies covered
- Achaogen Inc
- AmpliPhi Biosciences Corp
- Biolytics Pharma
- ContraFect Corp
- Inhibrx LP
- LegoChem Biosciences Inc
- Melinta Therapeutics Inc
- Shionogi & Co Ltd
- Novartis AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (2021-2032)
- 2.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (2021-2032)
- 2.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Average Price (2021-2032)
- 2.3 Resistant Pseudomonas Aeruginosa Infections Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cephalosporin
- 2.3.3 Lactam Drugs
- 2.3.4 Semi-Synthetic Penicillin
- 2.3.5 Others
- 2.4 Resistant Pseudomonas Aeruginosa Infections Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Home Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Product Type & Application
- 3.8 Global Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Established Date
- 3.9 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Achaogen Inc
- 4.1.1 Achaogen Inc Company Information
- 4.1.2 Achaogen Inc Business Overview
- 4.1.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.1.5 Achaogen Inc Recent Developments
- 4.2 AmpliPhi Biosciences Corp
- 4.2.1 AmpliPhi Biosciences Corp Company Information
- 4.2.2 AmpliPhi Biosciences Corp Business Overview
- 4.2.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.2.5 AmpliPhi Biosciences Corp Recent Developments
- 4.3 Biolytics Pharma
- 4.3.1 Biolytics Pharma Company Information
- 4.3.2 Biolytics Pharma Business Overview
- 4.3.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.3.5 Biolytics Pharma Recent Developments
- 4.4 ContraFect Corp
- 4.4.1 ContraFect Corp Company Information
- 4.4.2 ContraFect Corp Business Overview
- 4.4.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.4.5 ContraFect Corp Recent Developments
- 4.5 Inhibrx LP
- 4.5.1 Inhibrx LP Company Information
- 4.5.2 Inhibrx LP Business Overview
- 4.5.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.5.5 Inhibrx LP Recent Developments
- 4.6 LegoChem Biosciences Inc
- 4.6.1 LegoChem Biosciences Inc Company Information
- 4.6.2 LegoChem Biosciences Inc Business Overview
- 4.6.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.6.5 LegoChem Biosciences Inc Recent Developments
- 4.7 Melinta Therapeutics Inc
- 4.7.1 Melinta Therapeutics Inc Company Information
- 4.7.2 Melinta Therapeutics Inc Business Overview
- 4.7.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.7.5 Melinta Therapeutics Inc Recent Developments
- 4.8 Shionogi & Co Ltd
- 4.8.1 Shionogi & Co Ltd Company Information
- 4.8.2 Shionogi & Co Ltd Business Overview
- 4.8.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.8.5 Shionogi & Co Ltd Recent Developments
- 4.9 Novartis AG
- 4.9.1 Novartis AG Company Information
- 4.9.2 Novartis AG Business Overview
- 4.9.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio
- 4.9.5 Novartis AG Recent Developments
5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Scenario by Region
- 5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021-2032
- 5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2021-2026
- 5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2027-2032
- 5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2027-2032
- 5.4 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
- 5.4.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
- 5.4.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
- 5.5.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
- 5.7.1 South America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
- 5.7.3 South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032)
- 6.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032)
- 7.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain Analysis
- 8.1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Resistant Pseudomonas Aeruginosa Infections Drugs Production Mode & Process
- 8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors
- 8.2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
9 Global Resistant Pseudomonas Aeruginosa Infections Drugs Analyzing Market Dynamics
- 9.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends
- 9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Drivers
- 9.3 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Opportunities and Challenges
- 9.4 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst